Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Advanced Renal Cell Carcinoma
In brief
The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).
Key facts
- Study ID
- NCT01727336
- Run by
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- People needed
- 160
- Starts
- 2012-12-01
- Expected to finish
- 2017-11-01
- Last updated by the study team
- 2022-10-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Oncology Associates, PC - HOPE — Tucson, Arizona, United States
- Highlands Oncology Group, PA — Fayetteville, Arkansas, United States
- University of California Irvine Medical Center — Irvine, California, United States
- University of California, Los Angeles (UCLA) - Institute of Urologic Oncology — Los Angeles, California, United States
- Stanford Hospital and Clinics — Stanford, California, United States
- Rocky Mountain Cancer Centers — Aurora, Colorado, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- University of Miami — Miami, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
- Loyola University Chicago — Chicago, Illinois, United States
- Indiana University Health Melvin & Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Beth Israel Deaconess Med Center — Boston, Massachusetts, United States
- Lahey Hospital & Medical Center — Burlington, Massachusetts, United States
- Nebraska Methodist Hospital — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Cancer Center Hackensack UMC — Hackensack, New Jersey, United States
- University of New Mexico — Albuquerque, New Mexico, United States
- New York Oncology Hematology, P.C. — Albany, New York, United States
- North Shore LIJ Center for Advance Medicine — Lake Success, New York, United States
- Mem Sloan Kettering Cancer Center — New York, New York, United States
- NYU Cancer Institute — New York, New York, United States
- Levin Cancer Institute — Charlotte, North Carolina, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Northwest Cancer Specialists, P.C. — Tualatin, Oregon, United States
- Saint Luke's University Health Network — Bethlehem, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.